Efficacy of folinic acid in preventing oral mucositis in allogeneic hematopoietic stem cell transplant patients receiving MTX as prophylaxis for GVHD

J. Sugita, T. Matsushita, Haruhiko Kashiwazaki, M. Kosugi, S. Takahashi, K. Wakasa, S. Shiratori, M. Ibata, Y. Shono, A. Shigematsu, M. Obara, K. Fujimoto, T. Endo, M. Nishio, T. Kondo, S. Hashino, J. Tanaka, M. Asaka, M. Imamura

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

As the safety of folinic acid administration and its efficacy for reducing the toxicity of MTX remain controversial, we assessed the effect of folinic acid administration after MTX treatment for GVHD prophylaxis on the incidence of oral mucositis and acute GVHD. We retrospectively analyzed data for 118 patients who had undergone allogeneic hematopoietic SCT and had received MTX for GVHD prophylaxis. Multivariate analysis showed that systemic folinic acid administration significantly reduced the incidence of severe oral mucositis (odds ratio (OR)=0.13, 95% confidence interval (CI) 0.04-0.73, P=0.014). There was also a tendency for a lower incidence of severe oral mucositis in patients who received folinic acid mouthwash (OR=0.39, 95%CI 0.15-1.00, P=0.051). No significant difference was observed in the incidence of acute GVHD between patients who received systemic folinic acid administration and those who did not (P=0.88). Systemic folinic acid administration and mouthwash appear to be useful for reducing the incidence of severe oral mucositis in patients who have received allogeneic hematopoietic SCT using MTX as GVHD prophylaxis.

Original languageEnglish
Pages (from-to)258-264
Number of pages7
JournalBone Marrow Transplantation
Volume47
Issue number2
DOIs
Publication statusPublished - Feb 1 2012

Fingerprint

Stomatitis
Leucovorin
Hematopoietic Stem Cells
Transplants
Mouthwashes
Incidence
Odds Ratio
Confidence Intervals
Multivariate Analysis
Safety

All Science Journal Classification (ASJC) codes

  • Hematology
  • Transplantation

Cite this

Efficacy of folinic acid in preventing oral mucositis in allogeneic hematopoietic stem cell transplant patients receiving MTX as prophylaxis for GVHD. / Sugita, J.; Matsushita, T.; Kashiwazaki, Haruhiko; Kosugi, M.; Takahashi, S.; Wakasa, K.; Shiratori, S.; Ibata, M.; Shono, Y.; Shigematsu, A.; Obara, M.; Fujimoto, K.; Endo, T.; Nishio, M.; Kondo, T.; Hashino, S.; Tanaka, J.; Asaka, M.; Imamura, M.

In: Bone Marrow Transplantation, Vol. 47, No. 2, 01.02.2012, p. 258-264.

Research output: Contribution to journalArticle

Sugita, J, Matsushita, T, Kashiwazaki, H, Kosugi, M, Takahashi, S, Wakasa, K, Shiratori, S, Ibata, M, Shono, Y, Shigematsu, A, Obara, M, Fujimoto, K, Endo, T, Nishio, M, Kondo, T, Hashino, S, Tanaka, J, Asaka, M & Imamura, M 2012, 'Efficacy of folinic acid in preventing oral mucositis in allogeneic hematopoietic stem cell transplant patients receiving MTX as prophylaxis for GVHD', Bone Marrow Transplantation, vol. 47, no. 2, pp. 258-264. https://doi.org/10.1038/bmt.2011.53
Sugita, J. ; Matsushita, T. ; Kashiwazaki, Haruhiko ; Kosugi, M. ; Takahashi, S. ; Wakasa, K. ; Shiratori, S. ; Ibata, M. ; Shono, Y. ; Shigematsu, A. ; Obara, M. ; Fujimoto, K. ; Endo, T. ; Nishio, M. ; Kondo, T. ; Hashino, S. ; Tanaka, J. ; Asaka, M. ; Imamura, M. / Efficacy of folinic acid in preventing oral mucositis in allogeneic hematopoietic stem cell transplant patients receiving MTX as prophylaxis for GVHD. In: Bone Marrow Transplantation. 2012 ; Vol. 47, No. 2. pp. 258-264.
@article{f913de4ac7314e319d4e263bcf85ba87,
title = "Efficacy of folinic acid in preventing oral mucositis in allogeneic hematopoietic stem cell transplant patients receiving MTX as prophylaxis for GVHD",
abstract = "As the safety of folinic acid administration and its efficacy for reducing the toxicity of MTX remain controversial, we assessed the effect of folinic acid administration after MTX treatment for GVHD prophylaxis on the incidence of oral mucositis and acute GVHD. We retrospectively analyzed data for 118 patients who had undergone allogeneic hematopoietic SCT and had received MTX for GVHD prophylaxis. Multivariate analysis showed that systemic folinic acid administration significantly reduced the incidence of severe oral mucositis (odds ratio (OR)=0.13, 95{\%} confidence interval (CI) 0.04-0.73, P=0.014). There was also a tendency for a lower incidence of severe oral mucositis in patients who received folinic acid mouthwash (OR=0.39, 95{\%}CI 0.15-1.00, P=0.051). No significant difference was observed in the incidence of acute GVHD between patients who received systemic folinic acid administration and those who did not (P=0.88). Systemic folinic acid administration and mouthwash appear to be useful for reducing the incidence of severe oral mucositis in patients who have received allogeneic hematopoietic SCT using MTX as GVHD prophylaxis.",
author = "J. Sugita and T. Matsushita and Haruhiko Kashiwazaki and M. Kosugi and S. Takahashi and K. Wakasa and S. Shiratori and M. Ibata and Y. Shono and A. Shigematsu and M. Obara and K. Fujimoto and T. Endo and M. Nishio and T. Kondo and S. Hashino and J. Tanaka and M. Asaka and M. Imamura",
year = "2012",
month = "2",
day = "1",
doi = "10.1038/bmt.2011.53",
language = "English",
volume = "47",
pages = "258--264",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Efficacy of folinic acid in preventing oral mucositis in allogeneic hematopoietic stem cell transplant patients receiving MTX as prophylaxis for GVHD

AU - Sugita, J.

AU - Matsushita, T.

AU - Kashiwazaki, Haruhiko

AU - Kosugi, M.

AU - Takahashi, S.

AU - Wakasa, K.

AU - Shiratori, S.

AU - Ibata, M.

AU - Shono, Y.

AU - Shigematsu, A.

AU - Obara, M.

AU - Fujimoto, K.

AU - Endo, T.

AU - Nishio, M.

AU - Kondo, T.

AU - Hashino, S.

AU - Tanaka, J.

AU - Asaka, M.

AU - Imamura, M.

PY - 2012/2/1

Y1 - 2012/2/1

N2 - As the safety of folinic acid administration and its efficacy for reducing the toxicity of MTX remain controversial, we assessed the effect of folinic acid administration after MTX treatment for GVHD prophylaxis on the incidence of oral mucositis and acute GVHD. We retrospectively analyzed data for 118 patients who had undergone allogeneic hematopoietic SCT and had received MTX for GVHD prophylaxis. Multivariate analysis showed that systemic folinic acid administration significantly reduced the incidence of severe oral mucositis (odds ratio (OR)=0.13, 95% confidence interval (CI) 0.04-0.73, P=0.014). There was also a tendency for a lower incidence of severe oral mucositis in patients who received folinic acid mouthwash (OR=0.39, 95%CI 0.15-1.00, P=0.051). No significant difference was observed in the incidence of acute GVHD between patients who received systemic folinic acid administration and those who did not (P=0.88). Systemic folinic acid administration and mouthwash appear to be useful for reducing the incidence of severe oral mucositis in patients who have received allogeneic hematopoietic SCT using MTX as GVHD prophylaxis.

AB - As the safety of folinic acid administration and its efficacy for reducing the toxicity of MTX remain controversial, we assessed the effect of folinic acid administration after MTX treatment for GVHD prophylaxis on the incidence of oral mucositis and acute GVHD. We retrospectively analyzed data for 118 patients who had undergone allogeneic hematopoietic SCT and had received MTX for GVHD prophylaxis. Multivariate analysis showed that systemic folinic acid administration significantly reduced the incidence of severe oral mucositis (odds ratio (OR)=0.13, 95% confidence interval (CI) 0.04-0.73, P=0.014). There was also a tendency for a lower incidence of severe oral mucositis in patients who received folinic acid mouthwash (OR=0.39, 95%CI 0.15-1.00, P=0.051). No significant difference was observed in the incidence of acute GVHD between patients who received systemic folinic acid administration and those who did not (P=0.88). Systemic folinic acid administration and mouthwash appear to be useful for reducing the incidence of severe oral mucositis in patients who have received allogeneic hematopoietic SCT using MTX as GVHD prophylaxis.

UR - http://www.scopus.com/inward/record.url?scp=84857034929&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857034929&partnerID=8YFLogxK

U2 - 10.1038/bmt.2011.53

DO - 10.1038/bmt.2011.53

M3 - Article

C2 - 21423118

AN - SCOPUS:84857034929

VL - 47

SP - 258

EP - 264

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 2

ER -